This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Dial E, Duh M, Fournier A, Antras L, Rodermund D, Neary MP, Oh WK.Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma: a retrospective claims database analysis. 45th Annual Meeting of the American Society of Clinical Oncology: 261 abstr. 5112, 31 May 2009. Available from: URL: http://www.abstract.asco.org
Rights and permissions
About this article
Cite this article
Oral, compared with IV, angiogenesis inhibitor therapy may save money for patients and health care payers. Pharmacoecon. Outcomes News 580, 9 (2009). https://doi.org/10.2165/00151234-200905800-00022
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905800-00022